Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of Savara (NASDAQ:SVRA) in a report published on Friday, Marketbeat reports. The firm issued an overweight rating and a $8.00 price target on the stock.

Other equities research analysts also recently issued research reports about the stock. Evercore ISI reissued an “in-line” rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Savara in a research note on Thursday. Finally, HC Wainwright decreased their target price on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Savara presently has an average rating of “Moderate Buy” and a consensus target price of $9.86.

Savara Price Performance

NASDAQ:SVRA opened at $3.23 on Friday. The company has a market capitalization of $554.33 million, a P/E ratio of -7.51 and a beta of 0.92. The business’s 50-day moving average is $3.47 and its 200 day moving average is $3.99. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara has a 12 month low of $2.82 and a 12 month high of $5.70.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, equities research analysts forecast that Savara will post -0.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Joseph S. Mccracken bought 20,000 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the purchase, the director now directly owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction on Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the sale, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.13% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its stake in shares of Savara by 12.5% in the second quarter. Bank of New York Mellon Corp now owns 288,325 shares of the company’s stock worth $1,162,000 after buying an additional 32,142 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Savara by 967.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 44,008 shares of the company’s stock worth $177,000 after purchasing an additional 39,886 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after purchasing an additional 6,973 shares in the last quarter. Victory Capital Management Inc. acquired a new position in shares of Savara in the 2nd quarter valued at $527,000. Finally, Choreo LLC purchased a new stake in Savara during the second quarter worth $59,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.